• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Bausch Health Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/14/25 4:20:31 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BHC alert in real time by email
    bhc-20250514
    0000885590false00008855902025-05-142025-05-14

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
    MAY 14, 2025
    Date of report (Date of earliest event reported)
     Bausch Health Companies Inc.
    (Exact name of registrant as specified in its charter)
    British Columbia,Canada001-1495698-0448205
    (State or other jurisdiction of incorporation)(Commission file number)(IRS Employer Identification No.)
    2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8
    (Address of Principal Executive Offices) (Zip Code)
    (514) 744-6792
    (Registrant's telephone number, including area code)
    N/A
    (Former name or former address, if changed since last report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐          Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐          Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐          Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐          Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Shares, No Par ValueBHCNew York Stock ExchangeToronto Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐            




    Item 5.07. Submission of Matters to a Vote of Security Holders.
    On May 13, 2025, Bausch Health Companies Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the shareholders of the Company voted on the following four proposals, each of which is described in detail in the Company’s Management Proxy Circular and Proxy Statement. The results of each matter voted upon are as follows:
    Proposal No. 1: Election of Directors. The shareholders elected the following individuals to the Company’s Board of Directors, to serve until the close of the Company’s 2026 Annual Meeting of Shareholders, their successors are duly elected or appointed, or such director’s earlier resignation or removal:
    NameForWithheldBroker Non-Votes
    Thomas J. Appio208,400,5725,943,43656,339,806
    Christian A. Garcia 207,181,7627,162,24656,339,806
    Brett M. Icahn199,179,50815,164,50056,339,806
    Sarah B. Kavanagh208,164,2446,179,76456,339,806
    Frank D. Lee207,489,8916,854,11756,339,806
    Steven D. Miller206,805,7267,538,28256,339,806
    Richard C. Mulligan, Ph.D. 202,866,70311,477,30556,339,806
    John A. Paulson205,916,2868,427,72256,339,806
    Robert N. Power202,283,41812,060,59056,339,806
    Amy B. Wechsler, M.D.207,392,7986,951,21056,339,806
    Proposal No. 2: Advisory Vote on Executive Compensation. The shareholders approved, on a non-binding advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Compensation Discussion and Analysis section, executive compensation tables and accompanying narrative discussions contained in the Management Proxy Circular and Proxy Statement.
    ForAgainstAbstainBroker Non-Votes
    199,584,79013,233,3051,525,91356,339,806
    Proposal No. 3: Approval of the Bausch Health Companies Inc. 2025 Employee Stock Purchase Plan. The shareholders approved the Bausch Health Companies Inc. 2025 Employee Stock Purchase Plan.
    ForAgainstAbstainBroker Non-Votes
    209,243,2573,660,8411,439,91056,339,806
    Proposal No. 4: Appointment of the Independent Registered Public Accounting Firm. The shareholders appointed PricewaterhouseCoopers LLP as the auditors for the Company to hold office until the close of the 2026 Annual Meeting of Shareholders and authorized the Company’s Board of Directors to fix the auditors’ remuneration.
    ForWithheld
    266,669,0184,014,796




    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: May 14, 2025

    BAUSCH HEALTH COMPANIES INC.
     By:/s/ Seana Carson
    Seana Carson
    Executive Vice President, General Counsel

    Get the next $BHC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BHC

    DatePrice TargetRatingAnalyst
    8/2/2024$9.00 → $3.00Neutral → Underweight
    Piper Sandler
    7/10/2024$8.00Mkt Perform
    Raymond James
    9/20/2023$9.00 → $16.00Hold → Buy
    Jefferies
    6/16/2023Outperform → Market Perform
    TD Cowen
    7/29/2022Buy → Hold
    Truist
    7/29/2022$12.00 → $5.00Outperform → Sector Perform
    RBC Capital Mkts
    7/28/2022Overweight → Neutral
    JP Morgan
    6/13/2022$12.00Overweight
    JP Morgan
    More analyst ratings

    $BHC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program

      LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of the Drug Price Negotiation program.We look forward to engaging in open and transparent conversations with CMS, where we will share information on the value that XIFAXAN® delivers for the healthcare system in addition to sharing recommendations from The American Assoc

      1/17/25 9:25:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

      LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO):"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is

      12/12/24 7:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day

      LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support t

      12/5/24 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bausch Health downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously

      8/2/24 7:25:50 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James initiated coverage on Bausch Health with a new price target

      Raymond James initiated coverage of Bausch Health with a rating of Mkt Perform and set a new price target of $8.00

      7/10/24 8:35:33 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health upgraded by Jefferies with a new price target

      Jefferies upgraded Bausch Health from Hold to Buy and set a new price target of $16.00 from $9.00 previously

      9/20/23 7:27:08 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Financials

    Live finance-specific insights

    See more
    • Bausch Health Announces Third Quarter 2024 Results

      Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic (non-GAAP)1 basis, with growth in all segmentsConsolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $909 million, up 10%Raising full-year 2024 guidance LAVAL, QC / ACCESSWIRE / October 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2024 financial results and other key updates fro

      10/30/24 4:05:00 PM ET
      $BHC
      $NHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Hospital/Nursing Management
    • Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

      LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Wednesday, October 30, 2024Time:5:00 p.m. U.S. ESTWebcast:https://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in t

      10/9/24 4:05:00 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Announces Second Quarter 2024 Results

      Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10%Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / August 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2024 financial results and other key updates from the quarter."We continued our momentum in the second quarter, delivering our fifth

      7/31/24 12:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bausch Health Companies Inc.

      SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

      8/30/24 6:12:52 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Bausch Health Companies Inc.

      SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)

      8/19/24 5:48:41 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bausch Health Companies Inc. (Amendment)

      SC 13G/A - Bausch Health Companies Inc. (0000885590) (Subject)

      2/13/24 4:30:26 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Garcia Christian A was granted 54,347 shares, increasing direct ownership by 154% to 89,707 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      5/20/25 4:41:04 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Icahn Brett was granted 54,347 shares, increasing direct ownership by 34% to 216,246 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      5/20/25 4:38:49 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kavanagh Sarah B was granted 54,347 shares, increasing direct ownership by 30% to 236,359 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      5/20/25 4:37:11 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    SEC Filings

    See more
    • SEC Form 8-K filed by Bausch Health Companies Inc.

      8-K - Bausch Health Companies Inc. (0000885590) (Filer)

      5/20/25 8:15:42 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Bausch Health Companies Inc.

      8-K - Bausch Health Companies Inc. (0000885590) (Filer)

      5/15/25 4:10:10 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Bausch Health Companies Inc. (0000885590) (Filer)

      5/14/25 4:20:31 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Leadership Updates

    Live Leadership Updates

    See more
    • Bausch Health Appoints New Chief Medical Officer and Head of R&D

      LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,

      12/2/24 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Welcomes Two New Members to the Executive Leadership Team

      LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services, primarily at General Electric, Hewlett Packard, Novartis and Purdue Pharma. Upon JJ's arrival, John Barresi, the Company's Interim Chief Financial Officer, will resume his role as SVP, Controller.Aimee Lenar joined the Company on July 15, 2024 as Executive Vice President, US Pharm

      7/19/24 7:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day

      BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day. OIC Awareness Day aims to bring awareness to an often-overlooked side effect of opioids. This day will help patients suffering from OIC by breaking down the stigma and silence surrounding this condition."OIC Awareness Day will help bridge the gap between healthcare providers (HCPs), patients, and caregivers by providing

      12/5/23 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care